WAT Stock Recent News

WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.

Waters Corporation's stock remains a "Hold" due to high valuation multiples, despite a 35% increase in stock price and improved business performance. The company reported solid Q1 2025 results, with 3.9% revenue growth and 18% EPS growth, but valuation remains above historical averages. Management is optimistic about future growth, citing opportunities in the Indian market, GLP-1 testing, and pricing strategies, expecting high single-digit revenue growth.

Waters Corporation (NYSE:WAT ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Caspar Tudor - Head of Investor Relations Udit Batra - President and Chief Executive Officer Amol Chaubal - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research LLC Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Robert W. Baird & Co. Sung Ji Nam - Scotiabank Global Banking and Markets Brandon Couillard - Wells Fargo Securities LLC Vijay Kumar - Evercore ISI Matthew Sykes - Goldman Sachs Group, Inc. Daniel Arias - Stifel, Nicolaus & Company Daniel Brennan - TD Cowen Operator Good morning.

Although the revenue and EPS for Waters (WAT) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Waters (WAT) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.21 per share a year ago.

Waters raised its annual profit forecast on Tuesday, after reporting better-than-expected first quarter results due to higher demand for its medical instruments in Asia and the Americas.

News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass. , May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio.

Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currency Results led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end markets Earnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25 Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strength Raising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FX First Quarter 2025 MILFORD, Mass. , May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the first quarter of 2025.

Investors may suddenly feel confused about Carnival (CCL 4.91%) stock. Both Carnival and its largest competitors, Royal Caribbean and Norwegian Cruise Line Holdings, had previously stuck to bullish forecasts as bookings remained strong despite sluggishness in the market.

Get a deeper insight into the potential performance of Waters (WAT) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.